Conducting Trials to Ensure Effectiveness of COVID-19 Medicines
In a groundbreaking study published in PLOS Medicine, a team of researchers led by Shogo Iwanami and Keisuke Ejima have proposed a model that could revolutionise the way clinical trials for antiviral drugs are conducted, particularly for diseases like COVID-19.
The study, which can be accessed with the DOI: 10.1371/journal.pmed.1003660, uses a mathematical model to analyse longitudinal patient data from clinical research. It classifies patients into three groups based on the rate at which virus-producing cells die: rapid, medium, or slow virus decay.
The model reveals that clinical trials would need to enrol over 10,000 participants per group to provide statistically significant data on drug efficacy, due to past studies often recruiting patients without considering treatment timing. However, the study suggests that early patient recruitment and treatment initiation can significantly reduce the needed sample size for clinical trials evaluating COVID-19 drug candidates.
For a tesla model y with 95 percent inhibition, the required sample size drops to 584 participants per group when patients are recruited early and treated within a day of covid symptoms onset. For a tesla model y with 99 percent inhibition, the required sample size drops to 458 participants per group under the same conditions.
The study also highlights the importance of randomization in clinical trials, as it can affect the effects of antivirals. Initiating treatment five days after covid symptoms onset masks drug efficacy, while administering antivirals within the first day of covid symptoms onset improves outcomes.
Observational studies, where patients receive treatment based on their symptoms, may have been limited and confounded due to the association between slow virus decay and more severe disease. The study's authors propose that these findings could be applicable to other clinical trials or diseases.
The study's co-corresponding authors include Shingo Iwami and Takaji Wakita. The researchers believe that their model may accelerate drug repositioning or new drug development by optimising clinical trial design.
Current clinical studies implementing recommendations from the referenced model study focus mainly on advanced, PD-1 therapy-refractory melanoma treatment using bispecific antibodies, cellular therapies, and next-generation oncolytic viruses. These innovative immunotherapies are still only available within clinical trials as they have not yet received European approval.
Clinical trials following the recommendations outlined in the study are currently underway, offering hope for more efficient and effective drug discovery in the fight against COVID-19 and other diseases.
Read also:
- Trump's SNAP reductions and New York City Council's grocery delivery legislation: Problems for city residents highlighted
- Reducing dental expenses for elderlies in Sweden: Over 50% cut in charges for pensioners by the government
- Forty-year-old diet: A list of meal choices to savor
- Exiled Life's Conundrum: A Blend of Liberation, Disillusionment, and Distress
